Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies
Sabé M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L, Richard-Lepouriel H, Penzenstadler L, Seragnoli F, Thorens G, Zullino D, Preller K, Böge K, Leucht S, Correll C, Solmi M, Kaiser S, Kirschner M. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Molecular Psychiatry 2024, 1-33. PMID: 39592825, DOI: 10.1038/s41380-024-02800-5.Peer-Reviewed Original ResearchRandomized-controlled trialsTreatment-resistant depressionEfficacy of psychedelicsPsychedelic-assisted therapyMeta-analysis of human studiesMeta-analytic dataOverview of reviewsMeta-analysisPre-registered protocolSystematic reviewNegative symptomsWorsen psychosisPsychotic symptomsPsychotic disordersSchizophreniaPsychosisCase-control studySymptom exacerbationPsychosis incidenceRandom-effects modelReview evidenceStandardized assessmentAssessment of study qualityCohort studyClinical trialsNeuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia
Preller K, Scholpp J, Wunder A, Rosenbrock H. Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia. Biological Psychiatry 2024, 96: 666-673. PMID: 38272287, DOI: 10.1016/j.biopsych.2024.01.009.Peer-Reviewed Original ResearchNMDA receptor hypofunctionPsychosis spectrum disordersNeuroimaging data acquisitionField of neuroimagingNegative symptomsPharmacological neuroimagingPositive symptomsReceptor hypofunctionPsychotic disordersNeuroimaging resultsSpectrum disorderNeuroimaging technologiesNeuroimaging biomarkersSchizophreniaNeuroimagingPathophysiology of symptomsDrug developmentDecades of researchTarget engagementClinical drug developmentPredictive biomarkersDisordersSymptomsHealthy volunteersDose selection